Advances of n-3 polyunsaturated fatty acids in food allergy / 中华实用儿科临床杂志

Food allergy is a common allergic disease threatening the growth and development of infants and children.n-3 polyunsaturated fatty acids (PUFAs) are common nutrients in the diet, which have important structural functions and immunomodulatory effects.Their protective effect in food allergy has gradually become a potential research hotspot.This review highlights the function and immune regulation of PUFAs, the regulation of n-3 PUFAs on immunological indexes, the mechanism of food allergy, and the relationship between food allergy, and the impact of n-3 PUFAs on other allergic diseases.

Fasting: Recent development and prospects / 中华内分泌代谢杂志

Fasting is a dietary intervention based on restricted energy intake, which has different forms of frequency and intensity, and is effective at reducing body weight and improving metabolic health. The cellular and molecular mechanisms of fasting involve lipolysis, increase of thermogenesis, regulation of autophagy, modulation of β cell regeneration and suppression of inflammation. This review focuses on the updates of patterns, benefits, and mechanisms of fasting.

Risk Factors of Insomnia after Cerebral Middle Artery Infarction / 中国康复理论与实践

Objective To explore the type of circadian rhythms and risk factors for post-stroke insomnia. Methods From January, 2012 to June, 2014, the patients with cerebral middle artery infarction were divided into insomnia group (n=25) and control group (n=25). The general characterizations of the patients were collected. They were assessed with Morning and Evening Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Fatigue Severity Scale (FSS). Results The MEQ score was lower in the insomnia group than in the control group (t=2.676, P11) of National Institutes of Health Stroke Scale (NIHSS) was the independent risk foctor for post- stroke insomnia (OR=1.463, 95% CI=1.112- 1.925). The scores of ESS, PSQI, ISI and FSS were higher in the insomnia group than in the control group (t>5.609, P<0.001). The scores of ESS (r=0.334, P<0.05), FSS (r=0.535, P<0.01), PSQI (r=0.461, P=0.001) and ISI (r=0.504, P<0.01) were positively correlated with the NIHSS score. Conclusion The patients with post-stroke insomnia impair in circadian rhythms. High NIHSS score is the independent risk factor for post-stroke insom-nia.

Efficacy and safety of peginterferon α-2b in treatment of HBeAg-positive chronic Hepatitis B / 中华临床感染病杂志

Objective To assess the efficacy and safety of peginterferon ( PegIFN) α-2b in treatment of HBeAg-positive chronic hepatitis B ( CHB).Methods Thirty two patients with HBeAg-positive CHB admitted in Peking University Shenzhen Hospital during November 2013 and January 2014 were recruited in the study.Patients were center randomly assigned into two groups : 22 patients in test group were treated with 180 μg PegIFN α-2b, 1 /w for 48 wk; 10 patients in control group were treated with 180 μg PegIFN α-2a (Pegasys), 1 /w for 48wk.All patients were followed up for 24wk after treatment.Virology markers, HBV DNA levels and liver functions were monitored regularly , and adverse events were observed . Fisher’s exact test was used to compare the efficacy and safety between two groups .Results There were no statistically significant differences between the control group and test group in ALT normalization rates , HBV DNA negative rates and HBeAg serological conversion rates both at the end of treatment and at the end of 24-wk follow-up (all P >0.05).Both groups had similar adverse effect incidence rates (P >0.05), but retina disease occurred in 7 cases of test group, which was not observed in control group .Conclusion Compared with PegIFN α-2a, PegIFN α-2b has similar efficacy and safety for patients with HBeAg -positive CHB.

Comparison of efficacy and safety of pegylated interferon alfa-2a or adefovir dipivoxil monotherapy with combination therapy in HBeAg positive chronic hepatitis B patients / 中华传染病杂志

Objective To compare the clinical efficacy and safety of pegylated interferon α-2a (Peg IFN α-2a) or adefovir dipivoxil(ADV) monotherapy and their combination therapy in HBeAg positive chronic hepatitis B (CHB) patients. Methods An open randomized controlled multicenter clinical trial was performed. One hundred and twenty cases with CHB were divided into 3 groups: Peg IFN α-2a monotherapy (group A), ADV monotherapy (group B) and Peg IFN α-2a plus ADV combination therapy (group C). The virological response (VR), serological response (HBeAg, HBsAg clearance and seroconversion), biochemical response (BR) and sustained response (SR) were tested at week 24 and 48 of therapy and week 48 of follow-up after end of treatment (EOT) for'evaluation of therapeutic effects, safety and drug resistance. The efficacy was compared using X2 test. Results At week 48 of treatment, the VR (HBV DNA ≤500 copy/mL) rates were 36. 8%(14/38), 37. 5%(15/40) and 62. 9% (22/35), respectively in groups A, B and C; that in group C was higher than those in groups A and B (X2 = 4. 933, 4. 801, respectively; both P < 0. 05); HBeAg seroconversion rates in three groups were 44. 7% (17/38), 17. 5% (7/40) and 51. 4% (18/35), respectively. At week 48 of follow-up,SR rates in three groups were 34. 2%(13/38), 15. 0%(6/40) and 48. 6% (17/35), respectively; those in groups C and A were higher than that in group B (X2 = 9. 894,P<0. 01;X2 =3. 903, P<0. 05, respectively). Conclusions VRs at week 24 and 48 of Peg IFN α-2a plus ADV combination therapy are better than Peg IFN α-2a or ADV monotherapy. SRs at week 48 of follow-up after Peg IFN α-2a monotherapy and combination therapy are both better than ADV monotherapy.

Establishment and clinical application of fluorescent polymerase chain reaction for the determination of-88/-123 polymorphisms in the Myxovirus resistance protein A gene promoter / 中华传染病杂志

Objective To establish a fluorescent polymerase chain reaction (PCR) method for rapid, sensitive and specific determination of -88/-123 polymorphisms in Myxovirus resistance protein A (MxA) gene promoter so as to provide molecular biology tool for optimized interferon-a treatment in chronic hepatitis B patients. Methods Hepatitis B virus (HBV) genotyping,serum HBV DNA level,and- 88/- 123 polymorphisms in MxA gene promoter of patients who had been treated with interferon-α were detected. The statistical analysis was done by using SPSS software to understand the relationship between MxA gene polymorphisms and interferon-α treatment. Afterwards, an optimal fluorescent PCR system was established to determine -88/-123 polymorphisms in MxA gene promoter. The sensitivity and the specificity of this system were confirmed by DNA sequencing. P-value of chi square test, odds ratios of regression analysis and 95% confidence intervals were employed. Results Patients with- 88 G/T and - 123 C/A in the interferon-stimulated response element in MxA gene promoter were interferon-α sensitive, while patients with - 88 GIG and - 123 C/C were not interferon-α sensitive. The coincidence rate of this system was 99.65% in comparison with DNA sequencing.Conclusion MxA gene polymorphisms could be rapidly and sensitively determined by this fluorescent PCR system.

Early Rehabilitation and Nursing for Patients with Traumatic Brain Injury / 中国康复理论与实践

@#The traumatic brain injury(TBI)is the main cause of death and disability after earthquake.The rehabilitation should intervene as earlier as possible.This paper would introduce some rehabilitation approaches practically.

脑外伤功能障碍的早期康复和护理 / 中国康复理论与实践

@#The traumatic brain injury(TBI)is the main cause of death and disability after earthquake.The rehabilitation should intervene as earlier as possible.This paper would introduce some rehabilitation approaches practically.